Combining SNS01-T With Bortezomib Significantly Increases Its Effectiveness In Model Of Multiple Myeloma

Senesco Technologies, Inc. (“Senesco” or the “Company”) (NYSE MKT: SNT) announced today that the combination of bortezomib (the active component of VELCADE ® marketed by Millennium, The Takeda Oncology Company) and SNS01-T, the subject of Senesco’s on-going multiple myeloma clinical study, performs significantly better than either treatment alone in mouse xenograft models.

“We are very pleased to have shown that SNS01-T enhances the ability of bortezomib to inhibit tumor growth in the mouse model and could be a way to lower the dose and reduce the severity of treatment-related side effects of bortezomib ,” said Leslie J. Browne, Ph.D., President and CEO of Senesco. Dr. Browne added, “Since treatment increasingly involves combination therapy, it is important that SNS01-T works well when added to current multiple myeloma drugs.”

Mice implanted in the flank with human myeloma RPMI 8226 cells were treated with SNS01-T (0.375 mg/Kg IV), one of two different dose levels of bortezomib (0.2, 0.5 mg/Kg IP) alone or in combination with SNS01-T (0.375 mg/Kg IV). SNS01-T and bortezomib were administered twice weekly for 6 weeks. The study used an inactive nanoparticle as the control. SNS01-T monotherapy achieved 59% tumor growth inhibition, which exceeded that of bortezomib alone at either the 0.2 mg/kg dose (22% inhibition) or at 0.5 mg/kg (39 % inhibition). However, the combination of SNS01-T with 0.5 mg/kg of bortezomib resulted in 89 % tumor inhibition which was significantly more effective than either SNS01-T or bortezomib alone.

The Company recently reported that the combination of SNS01-T with lenalidomide (the active component of REVLIMID ® marketed by Celgene Corporation, also a leading treatment for multiple myeloma), strongly inhibited human multiple myeloma tumor growth during 6 weeks of treatment in mice and resulted in no regrowth of tumors after an additional 8 weeks without further treatment.

About Multiple Myeloma

Multiple myeloma is an incurable cancer of plasma cells, a type of white blood cell derived from B-lymphocytes, normally responsible for the production of antibodies, in which abnormal cells accumulate in the bone marrow leading to bone lesions and interfering with the production of normal blood cells. Senesco was previously granted orphan drug status for SNS01-T, the Company’s lead drug candidate for treatment of multiple myeloma.

If you liked this article you might like

Nursing Homes Cry All the Way to the Bank